Barclays PLC boosted its stake in shares of InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) by 20.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 16,491 shares of the medical instruments supplier’s stock after purchasing an additional 2,833 shares during the quarter. Barclays PLC’s holdings in InfuSystem were worth $336,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in INFU. UBS Group AG raised its stake in InfuSystem by 1,365.5% during the first quarter. UBS Group AG now owns 143,380 shares of the medical instruments supplier’s stock worth $2,919,000 after acquiring an additional 133,596 shares in the last quarter. Calamos Advisors LLC bought a new stake in shares of InfuSystem during the first quarter worth $1,776,000. Acuitas Investments LLC bought a new stake in shares of InfuSystem during the first quarter worth $1,485,000. Sowell Financial Services LLC grew its holdings in shares of InfuSystem by 3,270.0% during the first quarter. Sowell Financial Services LLC now owns 57,526 shares of the medical instruments supplier’s stock worth $1,187,000 after purchasing an additional 55,819 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of InfuSystem by 18.7% during the first quarter. Geode Capital Management LLC now owns 254,890 shares of the medical instruments supplier’s stock worth $5,189,000 after purchasing an additional 40,155 shares during the last quarter. Hedge funds and other institutional investors own 61.55% of the company’s stock.
Separately, Northland Securities restated a “buy” rating and set a $27.00 target price on shares of InfuSystem in a report on Wednesday, June 30th.
InfuSystem (NYSEAMERICAN:INFU) last posted its quarterly earnings results on Thursday, May 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $24.46 million during the quarter, compared to the consensus estimate of $24.50 million. InfuSystem had a net margin of 18.36% and a return on equity of 52.87%. Research analysts predict that InfuSystem Holdings Inc. will post 0.34 earnings per share for the current fiscal year.
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Read More: Candlestick
Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings Inc. (NYSEAMERICAN:INFU).
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.